tirzepatide side effects blindness Comparative ocular outcomes of versus other anti-obesity medications in people with obesity GLP-1 Medications and Your Vision:

Using both drug classes in combination could be reasonable not just in a sequential manner primarily driven by glycaemic control, but as a simultaneous initiation regardless of HbA 1c levels, particularly in people with established or at high risk for atherosclerotic CVD and those with CKD

Long-term safety data from decades of cosmetic use provides reassurance - no pattern of delayed toxicity, cumulative adverse effects, or serious safety signals has emerged despite widespread and prolonged use

Protect the medication from light and allow it to reach room temperature before administration, if necessary

TereshkoYDal BelloSDi LorenzoCPezSPittinoASartorRet al